Reports revealed that CD133 physically and functionally interacts with EGFR, facilitating AKT pathway activation in hepatocellular carcinoma and pancreatic cancer (Weng et al., 2016; Jang et al., 2017). Here, EGFR is linked to hepatocellular carcinoma.